New drug trial aims to tame seizures in rare childhood disorder
NCT ID NCT05249556
First seen Jun 27, 2026 · Last updated Aug 06, 2026 · Updated 2 times
Summary
This study tests whether the drug ganaxolone can reduce seizures in children aged 6 months to 2 years with CDKL5 deficiency disorder, a rare genetic condition causing hard-to-control seizures. Twenty children will receive either ganaxolone or a placebo alongside their usual seizure medication for 12 weeks. Researchers will measure changes in seizure frequency and monitor safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ganaxolone
- What this could lead to
- If it works, this could provide a new option to reduce seizures in very young children with CDKL5 deficiency disorder.
- What could go wrong
- This is a small early-stage trial with only 20 participants, so results may not apply to all children. The drug may not work better than placebo or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CDKL5 DEFICIENCY DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Hot baths tested as seizure treatment for rare childhood disorder
- Fever's impact on seizures in rare genetic disorder revealed
- Warm baths tested as seizure treatment for rare childhood disorder
- New drug shows promise for Tough-to-Treat seizures in kids
- New hope for rare epilepsy: drug shows promise in phase 3 trial